Gene expression correlating with response to paclitaxel in ovarian carcinoma xenografts

Maria Rosa Bani, Maria Ines Nicoletti, Nawal W. Alkharouf, Carmen Ghilardi, David Petersen, Eugenio Erba, Edward A. Sausville, Edison T. Liu, Raffaella Giavazzi

Research output: Contribution to journalArticle

59 Citations (Scopus)

Abstract

We have investigated gene expression profiles of human ovarian carcinomas in vivo during Taxol® (paclitaxel) treatment and observed a difference in expression. Nude mice bearing 1A9 or 1A9PTX22 xenografts were given 60 mg/kg of paclitaxel. Therapeutic efficacy was achieved for 1A9, while 1A9PTX22 did not respond. Tumor tissues harvested 4 and 24 h after treatment were evaluated by cDNA microarray against untreated tumors. Paclitaxel caused the modulation of more genes in 1A9 than in 1A9PTX22 tumors, in accordance to their therapeutic response. Most gene expression alterations were detected 24 h after paclitaxel administration and affected genes involved in various biological functions including cell cycle regulation and cell proliferation (CDC2, CDKN1A, PLAB, and TOP2A), apoptosis (BNIP3 and PIG8), signal transduction and transcriptional regulation (ARF1, ATF2, FOS, GNA11, HDAC3, MADH2, SLUG, and SPRY4), fatty acid biosynthesis and sterol metabolism (FDPS, IDI1, LIPA, and SC5D), and IFN-mediated signaling (G1P3, IFI16, IFI27, IFITM1, and ISG15). The modulation of two representative genes, CDKN1A and TOP2A, was validated by Northern analyses on a panel of seven ovarian carcinoma xenograft models undergoing treatment with paclitaxel. We found that the changes in expression level of these genes was strictly associated with the responsiveness to paclitaxel. Our study shows the feasibility of obtaining gene expression profiles of xenografted tumor models as a result of drug exposure. This in turn might provide insights related to the drugs' action in vivo that will anticipate the response to treatment manifested by tumors and could be the basis for novel approaches to molecular pharmacodynamics.

Original languageEnglish
Pages (from-to)111-121
Number of pages11
JournalMolecular Cancer Therapeutics
Volume3
Issue number2
Publication statusPublished - Feb 2004

Fingerprint

Paclitaxel
Heterografts
Carcinoma
Gene Expression
Neoplasms
Transcriptome
Genes
Gastropoda
Feasibility Studies
Sterols
Oligonucleotide Array Sequence Analysis
Nude Mice
Pharmaceutical Preparations
Signal Transduction
Cell Cycle
Fatty Acids
Cell Proliferation
Apoptosis
Therapeutics

ASJC Scopus subject areas

  • Oncology
  • Drug Discovery
  • Pharmacology

Cite this

Gene expression correlating with response to paclitaxel in ovarian carcinoma xenografts. / Bani, Maria Rosa; Nicoletti, Maria Ines; Alkharouf, Nawal W.; Ghilardi, Carmen; Petersen, David; Erba, Eugenio; Sausville, Edward A.; Liu, Edison T.; Giavazzi, Raffaella.

In: Molecular Cancer Therapeutics, Vol. 3, No. 2, 02.2004, p. 111-121.

Research output: Contribution to journalArticle

Bani, MR, Nicoletti, MI, Alkharouf, NW, Ghilardi, C, Petersen, D, Erba, E, Sausville, EA, Liu, ET & Giavazzi, R 2004, 'Gene expression correlating with response to paclitaxel in ovarian carcinoma xenografts', Molecular Cancer Therapeutics, vol. 3, no. 2, pp. 111-121.
Bani, Maria Rosa ; Nicoletti, Maria Ines ; Alkharouf, Nawal W. ; Ghilardi, Carmen ; Petersen, David ; Erba, Eugenio ; Sausville, Edward A. ; Liu, Edison T. ; Giavazzi, Raffaella. / Gene expression correlating with response to paclitaxel in ovarian carcinoma xenografts. In: Molecular Cancer Therapeutics. 2004 ; Vol. 3, No. 2. pp. 111-121.
@article{b12e483dc0ea49abb990d19aff9b0c14,
title = "Gene expression correlating with response to paclitaxel in ovarian carcinoma xenografts",
abstract = "We have investigated gene expression profiles of human ovarian carcinomas in vivo during Taxol{\circledR} (paclitaxel) treatment and observed a difference in expression. Nude mice bearing 1A9 or 1A9PTX22 xenografts were given 60 mg/kg of paclitaxel. Therapeutic efficacy was achieved for 1A9, while 1A9PTX22 did not respond. Tumor tissues harvested 4 and 24 h after treatment were evaluated by cDNA microarray against untreated tumors. Paclitaxel caused the modulation of more genes in 1A9 than in 1A9PTX22 tumors, in accordance to their therapeutic response. Most gene expression alterations were detected 24 h after paclitaxel administration and affected genes involved in various biological functions including cell cycle regulation and cell proliferation (CDC2, CDKN1A, PLAB, and TOP2A), apoptosis (BNIP3 and PIG8), signal transduction and transcriptional regulation (ARF1, ATF2, FOS, GNA11, HDAC3, MADH2, SLUG, and SPRY4), fatty acid biosynthesis and sterol metabolism (FDPS, IDI1, LIPA, and SC5D), and IFN-mediated signaling (G1P3, IFI16, IFI27, IFITM1, and ISG15). The modulation of two representative genes, CDKN1A and TOP2A, was validated by Northern analyses on a panel of seven ovarian carcinoma xenograft models undergoing treatment with paclitaxel. We found that the changes in expression level of these genes was strictly associated with the responsiveness to paclitaxel. Our study shows the feasibility of obtaining gene expression profiles of xenografted tumor models as a result of drug exposure. This in turn might provide insights related to the drugs' action in vivo that will anticipate the response to treatment manifested by tumors and could be the basis for novel approaches to molecular pharmacodynamics.",
author = "Bani, {Maria Rosa} and Nicoletti, {Maria Ines} and Alkharouf, {Nawal W.} and Carmen Ghilardi and David Petersen and Eugenio Erba and Sausville, {Edward A.} and Liu, {Edison T.} and Raffaella Giavazzi",
year = "2004",
month = "2",
language = "English",
volume = "3",
pages = "111--121",
journal = "Molecular Cancer Therapeutics",
issn = "1535-7163",
publisher = "American Association for Cancer Research Inc.",
number = "2",

}

TY - JOUR

T1 - Gene expression correlating with response to paclitaxel in ovarian carcinoma xenografts

AU - Bani, Maria Rosa

AU - Nicoletti, Maria Ines

AU - Alkharouf, Nawal W.

AU - Ghilardi, Carmen

AU - Petersen, David

AU - Erba, Eugenio

AU - Sausville, Edward A.

AU - Liu, Edison T.

AU - Giavazzi, Raffaella

PY - 2004/2

Y1 - 2004/2

N2 - We have investigated gene expression profiles of human ovarian carcinomas in vivo during Taxol® (paclitaxel) treatment and observed a difference in expression. Nude mice bearing 1A9 or 1A9PTX22 xenografts were given 60 mg/kg of paclitaxel. Therapeutic efficacy was achieved for 1A9, while 1A9PTX22 did not respond. Tumor tissues harvested 4 and 24 h after treatment were evaluated by cDNA microarray against untreated tumors. Paclitaxel caused the modulation of more genes in 1A9 than in 1A9PTX22 tumors, in accordance to their therapeutic response. Most gene expression alterations were detected 24 h after paclitaxel administration and affected genes involved in various biological functions including cell cycle regulation and cell proliferation (CDC2, CDKN1A, PLAB, and TOP2A), apoptosis (BNIP3 and PIG8), signal transduction and transcriptional regulation (ARF1, ATF2, FOS, GNA11, HDAC3, MADH2, SLUG, and SPRY4), fatty acid biosynthesis and sterol metabolism (FDPS, IDI1, LIPA, and SC5D), and IFN-mediated signaling (G1P3, IFI16, IFI27, IFITM1, and ISG15). The modulation of two representative genes, CDKN1A and TOP2A, was validated by Northern analyses on a panel of seven ovarian carcinoma xenograft models undergoing treatment with paclitaxel. We found that the changes in expression level of these genes was strictly associated with the responsiveness to paclitaxel. Our study shows the feasibility of obtaining gene expression profiles of xenografted tumor models as a result of drug exposure. This in turn might provide insights related to the drugs' action in vivo that will anticipate the response to treatment manifested by tumors and could be the basis for novel approaches to molecular pharmacodynamics.

AB - We have investigated gene expression profiles of human ovarian carcinomas in vivo during Taxol® (paclitaxel) treatment and observed a difference in expression. Nude mice bearing 1A9 or 1A9PTX22 xenografts were given 60 mg/kg of paclitaxel. Therapeutic efficacy was achieved for 1A9, while 1A9PTX22 did not respond. Tumor tissues harvested 4 and 24 h after treatment were evaluated by cDNA microarray against untreated tumors. Paclitaxel caused the modulation of more genes in 1A9 than in 1A9PTX22 tumors, in accordance to their therapeutic response. Most gene expression alterations were detected 24 h after paclitaxel administration and affected genes involved in various biological functions including cell cycle regulation and cell proliferation (CDC2, CDKN1A, PLAB, and TOP2A), apoptosis (BNIP3 and PIG8), signal transduction and transcriptional regulation (ARF1, ATF2, FOS, GNA11, HDAC3, MADH2, SLUG, and SPRY4), fatty acid biosynthesis and sterol metabolism (FDPS, IDI1, LIPA, and SC5D), and IFN-mediated signaling (G1P3, IFI16, IFI27, IFITM1, and ISG15). The modulation of two representative genes, CDKN1A and TOP2A, was validated by Northern analyses on a panel of seven ovarian carcinoma xenograft models undergoing treatment with paclitaxel. We found that the changes in expression level of these genes was strictly associated with the responsiveness to paclitaxel. Our study shows the feasibility of obtaining gene expression profiles of xenografted tumor models as a result of drug exposure. This in turn might provide insights related to the drugs' action in vivo that will anticipate the response to treatment manifested by tumors and could be the basis for novel approaches to molecular pharmacodynamics.

UR - http://www.scopus.com/inward/record.url?scp=4444331074&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=4444331074&partnerID=8YFLogxK

M3 - Article

C2 - 14985451

AN - SCOPUS:4444331074

VL - 3

SP - 111

EP - 121

JO - Molecular Cancer Therapeutics

JF - Molecular Cancer Therapeutics

SN - 1535-7163

IS - 2

ER -